2. Signaling Pathways
  3. GPCR/G Protein
  4. P2Y Receptor

P2Y Receptor

P2Y Receptor

Related Products

PDF 0.7 MB

P2Y receptors are a class of G protein-coupled receptors (GPCRs) activated by extracellular nucleotides (ATP, UTP, and UDP). There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain.

The P2Y family can be further divided into a subfamily of five P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11Rs (“P2Y1-like”) that stimulate phospholipase C (PLC) through Gq protein and a second subfamily of P2Y12, P2Y13, and P2Y14Rs (“P2Y12-like”) that inhibit adenylate cyclase through Gi protein. Other effector pathways have been documented, such as coupling of the P2Y11R to Gs as well as to Gq in some cells to induce stimulation of cyclic AMP production.

P2Y Receptor Isoform Specific Products:

P2Y Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-123669
    R-138727
    		Inhibitor
    R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC50 of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.
    R-138727
  • HY-103172
    8-Aminoadenine
    		Inhibitor 98.34%
    8-Aminoadenine is an adenine receptor 1 (rAde1R) inhibitor with a Ki of 6.51 μM in rat and 0.0341 μM in human. 8-Aminoadenine inhibits isoprenaline-induced cAMP accumulation and adenine uptake in astrocytoma cells expressing rAde1R. 8-Aminoadenine serves as a lead structure for the development of adenine receptor ligands to elucidate the functions of the adenine receptor family.
    8-Aminoadenine
  • HY-101308
    MRS2179 tetrasodium
    		Antagonist
    MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors. MRS2179 tetrasodium inhibits platelet aggregation.
    MRS2179 tetrasodium
  • HY-15284S1
    Prasugrel-d3
    		Inhibitor 98.58%
    Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel-d<sub>3</sub>
  • HY-RS09922
    P2RY13 Human Pre-designed siRNA Set A
    		Inhibitor

    P2RY13 Human Pre-designed siRNA Set A contains three designed siRNAs for P2RY13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2RY13 Human Pre-designed siRNA Set A
  • HY-107372H
    UTP trisodium salt, 100 mM Solution, PCR Grade
    		Activator
    UTP (Uridine 5'-triphosphate) trisodium salt, 100 mM Solution, PCR Grade is a solution prepared from uridine triphosphate at a concentration of 100 mM, free of DNase, RNase and phosphatase contamination, suitable for molecular biology research. Uridine triphosphate (HY-107372) is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate activates membrane-bound P2Y2 receptors.
    UTP trisodium salt, 100 mM Solution, PCR Grade
  • HY-108649A
    MRS2768 tetrasodium salt
    		Agonist 98.70%
    MRS2768 tetrasodium salt is a moderately potent and selective P2Y2 receptor agonist. MRS2768 tetrasodium salt has a protective effect on cardiomyocytes from ischemic damage in vivo and in vitro.
    MRS2768 tetrasodium salt
  • HY-172417
    Becondogrel
    		Antagonist 99.39%
    Becondogrel (2-Oxoclopidogrel) is the metabolite of Clopidogrel (HY-15283). Becondogrel irreversibly inhibits P2Y12 receptor, thereby inhibiting platelet aggregation and thrombosis.
    Becondogrel
  • HY-110092A
    PSB-1114 triethylamine
    		Agonist
    PSB-1114 triethylamine is a potent, enzymatically stable, and subtype-selective P2Y2 receptor agonist with an EC50 of 134 nM. PSB-1114 triethylamine displays >50-fold selectivity versus the P2Y4 (EC50 of 9.3 μM) and P2Y6 (EC50 of 7.0 μM) receptors.
    PSB-1114 triethylamine
  • HY-123490
    Regrelor disodium
    		Antagonist 99.89%
    Regrelor disodium (INS 50589) is a platelet P2Y12 receptor antagonist. Regrelor disodium is a well-tolerated, reversible ADP competitive antagonist. Regrelor disodium inhibits cell proliferation. Regrelor disodium can be used in inflammation-related research.
    Regrelor disodium
  • HY-125989B
    2-Methylthio-AMP diTEA
    		Antagonist ≥98.0%
    2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation.
    2-Methylthio-AMP diTEA
  • HY-N7032S
    Uridine 5′-diphosphoglucose-13C disodium
    		98.8%
    Uridine 5′-diphosphoglucose-13C (UDP-D-Glucose-13C) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032). Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
    Uridine 5′-diphosphoglucose-<sup>13</sup>C disodium
  • HY-115273A
    MRS 2179 ammonium
    		Antagonist 99.34%
    MRS 2179 ammonium is a selective and competitive antagonist for P2Y1 receptor, with KB of 0.177 μM.
    MRS 2179 ammonium
  • HY-N7032S1
    Uridine 5′-diphosphoglucose-13C6 disodium
    		98.35%
    Uridine 5′-diphosphoglucose-13C6 (UDP-D-Glucose-13C6) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032). Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
    Uridine 5′-diphosphoglucose-<sup>13</sup>C<sub>6</sub> disodium
  • HY-137626A
    Sp-ATPαS tetrasodium solution (100mM)
    		Antagonist 98.60%
    Sp-ATPαS tetrasodium is a thiophosphonate analogue of ATP. Sp-ATPαS tetrasodium is a competitive antagonist of the human P2Y1 receptor and can inhibit the calcium signal induced by ADP. Sp-ATPαS tetrasodium has higher metabolic stability than ATP. Sp-ATPαS tetrasodium can be used to study the binding mode of metal-nucleotide in enzymatic reactions.
    Sp-ATPαS tetrasodium solution (100mM)
  • HY-N7740
    Adenosine 2',5'-diphosphate sodium
    		Antagonist 99.0%
    Adenosine 2',5'-diphosphate sodium is a competitive P2Y1 antagonist. Adenosine 2',5'-diphosphate sodium exhibits non-selective antagonism at recombinant and human platelet P2X1 receptors.
    Adenosine 2',5'-diphosphate sodium
  • HY-113044
    Uridine 5′-diphosphoglucose
    		Agonist
    Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
    Uridine 5′-diphosphoglucose
  • HY-111755
    P2Y12 antagonist 2
    		Antagonist
    P2Y12 antagonist 2 is a potent P2Y12 receptor antagonist. P2Y12 antagonist 2 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. P2Y12 antagonist 2 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. P2Y12 antagonist 2 can be used to research thromboembolic disorders.
    P2Y12 antagonist 2
  • HY-19638
    Cangrelor
    		Antagonist
    Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist.
    Cangrelor
  • HY-108661
    NF546
    		Agonist
    NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
    NF546
Cat. No. Product Name / Synonyms Application Reactivity
P2Y Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.